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ther reductions in costs with no detriment to benefits
were seen when modified risk criteria were in the guide-
lines were not followed and bone mass density measure-
ments and diagnostic testing were excluded. Sensitivity
analysis of the results identified sex as a major influence
on cost effectiveness. When men were excluded, favour-
able reductions were seen in the cost per fracture averted
and cost per QALY saved.
CONCLUSION: When managing corticosteroid-induced
osteoporosis in respiratory patients, this study showed
that it was more cost-effective to use modified guidelines
than existing guidelines. The modifications proposed are
to include risk assessment criteria for sex, and use of in-
termittent oral and inhaled corticosteroids.
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The prevalence of osteoporosis is expected to increase
from 10.1 million in 1996 to 14.7 million in 2015 (NOF,
1997). Medical cost was estimated to be $13.8 billion in
1995, but growth has not been predicted.
OBJECTIVE: To estimate the direct medical cost of os-
teoporotic fractures in the US in 2000-2025.
METHODS: Cost of osteoporosis for women aged 50 to 99
was predicted using a Markov model, which tracked cohort
movements across fracture-outcome states. We ran 50 con-
secutive cohorts from age 50 to 99, each with a 25-year fol-
low-up. Average cost at each patient age was adjusted by os-
teoporosis attribution rates. Then the population of women
aged 50 to 99 was multiplied by the age-specific average
cost to determine total cost by age within each year (2000–
2025). Because fracture incidence rates were unavailable for
men and for “other” fracture types in women, these costs
were estimated by multiplying base year costs by the respec-
tive population increases over time. Unit costs for hospital
inpatient care were estimated by fracture type from the Na-
tionwide Inpatient Sample, applying high-cost outlier edits
and a 20% payer discount. For non-hip fractures, we multi-
plied mean hospital charges by 0.10 to 0.159 to reflect the
low proportion of fractures resulting in hospitalization. Pri-
mary and long-term care costs were obtained from pub-
lished national estimates.
RESULTS: In 2000, we estimate that osteoporosis caused
1.2 million fractures in the U.S. at a direct medical cost of
$16.2 billion. Three-fourths of fractures occurred in indi-
viduals age 75 and older, and over one third (35%) oc-
curred in nursing facilities. Annual cost is projected to
grow by 58% to $25.6 billion in 2025.
CONCLUSION: Without change in medical practice,
this preventable disease will impose a substantial burden
on the US health-care system as the population ages.
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OBJECTIVE: After community pharmacists in five states
attended a Women’s Health Pharmaceutical Care certifi-
cation program, we evaluated pharmacists’ interventions
provided to osteoporosis patients.
METHODS: Pharmacists participated in a six-topic
Women’s Health Educational program including self-
study modules and live continuing education. Pharma-
cists faxed intervention-report forms to researchers re-
porting patient’s problems, pharmacist interventions, and
intervention outcomes for patients. This report focuses
on interventions for osteoporosis.
RESULTS: Female patients (n  140) identified with
medication issues related to osteoporosis were provided
pharmaceutical care. The mean age of these patients was
51.29, SD 9.85. The most common drug-related prob-
lems were untreated indications or the need for an addi-
tional drug (42.9%), and side effects from a medication
(17.9%). The highest adherence problem was that pa-
tients discontinued their medications (51.4%). In 90% of
the cases, the pharmacists provided interventions directly
to the patients by giving patient education about medica-
tions, disease management, and alternative therapy.
Pharmacists suggested the patients talk with their physi-
cian about prescription products in 37.1% of the cases.
In another 17.9% of cases they contacted physicians for
recommended medications or to schedule an appoint-
ment for the patient. About 25% of the patients were
scheduled to see their physician or received a new drug
from the physicians. Pharmacists recommended over-the-
counter (OTC) drugs or vitamins and minerals to 35.7%
patients. In 32.9% of the cases, the patient added OTC
drugs or vitamins and minerals. Pharmacists spent an av-
erage of 14 minutes with each patient to identify and pro-
vide interventions for specific problems. In 85.1% of the
interventions the pharmacist felt confident to provide
pharmaceutical care for the osteoporosis patients.
CONCLUSIONS: Community pharmacists are in a
prime location to identify patients at risk for medication
problems related to osteoporosis. These data suggest that
when pharmacists identify problems with drug therapy,
positive outcomes occur.
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